CRATOS - Evaluation of Cratos™ Branch Stent Graft System in Treatment of Descending Aorta Lesions

Exclusion Criteria

• •1. Concomitant disease of the ascending aorta or aneurysm of the abdominal aorta requiring repair
• •2. Previous endovascular repair of the ascending aorta
• •3. Infected aorta, active systemic infection
• •4. Surgery within 30 days prior to enrolment with the exception of placement of vascular conduit for access .
• •5. Life expectancy \<1 years
• •6. Myocardial infarction within 6 weeks prior to treatment
• •7. Stroke within 6 weeks prior to treatment.
• •8. Pregnant or breastfeeding female
• •9. Patient has an active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication) that may place the patient at increased risk of endovascular infection.
• •10. Degenerative connective tissue disease, e.g., Marfan's or Ehlers-Danlos Syndrome
• •11. Participation in another drug or medical device study within one year of study enrolment
• •12. Known history of drug abuse within one year of treatment
• •13. Tortuous or stenotic iliac and/or femoral arteries preventing introducer sheath insertion and the inability to use a conduit for vascular access
• •14. Planned coverage of celiac artery
• •15. Allergic to contrast agents, anaesthetics and delivery materials
• •16. Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known hypersensitivity to heparin
• •17. Patient with a history of a hypercoagulability disorder and/or is currently in a hypercoagulability state
• •18. Persistent refractory shock (systolic blood pressure \<90 mm Hg)
• •19. Renal failure defined as patients with an estimated Glomerular Filtration Rate (eGFR) \<30 (ml/min/1.73 m2) or currently requiring dialysis
• •20. Contraindications to antiplatelet drugs and anticoagulants
• •21. Investigator judged that not suitable for interventional treatment.